FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exemption on federally funded research
Three small-cap stocks have intrigued Stocktwits users the most among the biotech sector this year, thanks to promising data from clinical trials and a leadership shuffle.
Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts.
